THERAPY DOSSIER · th-d13c4fa92293

RAGE antagonist peptide (RAP); ganciclovir for ablation of S100a4-positive cells in S100a4-TK mice; S100a4 haploinsufficiency as a genetic comparator

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31124787 ↗2019Mixed findings

Cell non-autonomous functions of S100a4 drive fibrotic tendon healing.

MouseOtherC57BL/6J (000664); transgenic lines S100A4-GFP (012893), S100a4-TK (012902), S100a4 knockout (012904), S100a4-Cre (012641), ROSA-Ai9 (007909), Csf1r-iCre (019098)Male and femalen = RAP study n = 13 per group; S100a4 haploinsufficient versus…Intraperitoneal injectionRAP 100 ug per injection; ganciclovir 75 mg/kg; tamoxifen 1…RAP given on days 5 to 10 after surgery; ganciclovir given days 5 to 10 or days…

Model: Complete transection and surgical repair of the flexor digitorum longus tendon; complete transection and repair of the Achilles tendon in a second model

S100a4 haploinsufficiency improved tendon healing, with a 36% increase in metatarsophalangeal flexion angle (p = 0.04), a 43% decrease in gliding resistance (p = 0.028) and a 35% increase in maximum load at failure (p = 0.003); RAGE antagonist peptide gave partial benefit, improving flexion angle b…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…